Aphria Inc. Stock Sinks As Market Gains: What You Should Know

Aphria公司股票随着市场收益下跌：你应该知道什么

2019-03-13 05:45:09 Zacks

本文共920个字，阅读需3分钟


颐合恒瑞医疗

医用可吸收材料研发
融资需求 暂不透露

推荐
In the latest trading session, Aphria Inc. closed at $9.57, marking a -1.95% move from the previous day. This move lagged the S&P 500's daily gain of 0.3%. Elsewhere, the Dow lost 0.38%, while the tech-heavy Nasdaq added 0.44%.

在最近的交易时段， Aphria Inc .收于9.57美元，较前一交易日下跌了-1.95%。这一举措落后于标普500指数0.3%的日涨幅。在其他地区，道琼斯指数下跌了0.38%，而科技股云集的纳斯达克指数上涨了0.44%。

Prior to today's trading, shares of the company had gained 16.47% over the past month. This has outpaced the Medical sector's gain of 2.07% and the S&P 500's gain of 2.91% in that time.

在今天的交易之前，该公司的股票在过去一个月里上涨了16.47%。这一增幅超过了医疗行业2.07%的增幅，也超过了标普500指数当时2.91%的涨幅。

APHA will be looking to display strength as it nears its next earnings release. On that day, APHA is projected to report earnings of -$0.04 per share, which would represent a year-over-year decline of 166.67%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $41.11 million, up 403.74% from the year-ago period.

APHA 将在接近下一次收益公布时显示实力。当日， APHA 预计报告每股收益为0.04美元，同比下降166.67%。与此同时， Zacks 的收入预期为4111万美元，同比增长403.74%。

APHA's full-year Zacks Consensus Estimates are calling for earnings of $0.11 per share and revenue of $129.24 million. These results would represent year-over-year changes of -21.43% and +344.96%, respectively.

APHA 的全年 Zacks 共识估计要求每股收益0.11美元，收入1.2924亿美元。这些结果将分别代表同比变动-21.43%和+344.96%。

Any recent changes to analyst estimates for APHA should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

投资者还应注意 APHA 分析师估计的任何近期变化。这些修订通常反映最新的短期业务趋势，这些趋势可能会经常变化。因此，我们可以将正面估计修订解读为公司经营前景的良好标志。

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

我们的研究表明，这些估计的变化与近期股票价格直接相关。为了从中获益，我们开发了 ZackRank ，一种考虑到这些估计更改并提供可操作的评级系统的专有模型。

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 20.54% higher within the past month. APHA is currently sporting a Zacks Rank of #3 (Hold).

Zacks Rank 从#1（ Strong Buy ）到#5（ Strong Sell ），经过外部审计，其业绩表现良好，自1988年以来#1股票的年均回报率为+25%。Zacks 共识 EPS 估计在过去一个月里上涨了20.54%。APHA 目前正在运动的 Zacks 排名第3（持有）。

In terms of valuation, APHA is currently trading at a Forward P/E ratio of 86.76. Its industry sports an average Forward P/E of 25.01, so we one might conclude that APHA is trading at a premium comparatively.

估值方面， APHA 目前的远期市盈率为86.76倍。该行业的平均远期市盈率为25.01，因此我们可以得出这样的结论： APHA 的交易价格相对较高。

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.

医疗产品行业是医疗行业的一部分.该集团拥有75个 Zacks 行业排名，在所有250多个行业中排名前30%。

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Zacks 行业排名包括从最好到最坏的顺序，平均 Zacks 排名的个别公司在每个行业。我们的研究表明，排名前50%的行业表现优于排名后半的行业，表现为2比1。

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

一定要遵循所有这些股票移动的指标，以及更多的 Zacks 。

aphria近期有个收益没达标，pe在同行里变高了，股价需要回调一下